Prevalence of infections by
Helicobacter pylori, a pathogen involved in a number of gastrointestinal diseases, remains high in developing countries. Management of infections by eradication is not always an option.
Lactobacillus reuteri (
L. reuteri) DSMZ17648 (Pylopass™/Lonza) specifically co-aggregates
H. pylori
[...] Read more.
Prevalence of infections by
Helicobacter pylori, a pathogen involved in a number of gastrointestinal diseases, remains high in developing countries. Management of infections by eradication is not always an option.
Lactobacillus reuteri (
L. reuteri) DSMZ17648 (Pylopass™/Lonza) specifically co-aggregates
H. pylori in vitro and was shown to reduce
13C urea breath test
in vivo. In this pilot study, we tried to replicate previous findings in an independent sample and to evaluate effects of spray-drying
vs. freeze-drying of cultures. A single-blinded, placebo-controlled study was done in 22
H. pylori positive, asymptomatic adults.
H. pylori levels were determined by
13C-urea-breath method after 14 days of supplementation, as well as after 6, 12, and 24 weeks follow-up. In the test group, but not in the placebo group, a significant reduction of
H. pylori was observed. For the first time, spray-dried cells of
L. reuteri DSMZ17648 have been used in a human study and results are in line with the first study results, supplementing with freeze-dried material. This is of special interest as spray-drying results in dead cell material, meaning that the effect of
L. reuteri must be independent of its probiotic activity. These results confirm the potential of Pylopass™ as a novel way to reduce the load of
H. pylori.
Full article